Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Studies of NVP-BEZ235 in Melanoma

Author(s): Joshua A. Sznol, Lucia B. Jilaveanu, Harriet M. Kluger.

Abstract:

The PI3k pathway represents an attractive target for drug development in melanoma, as numerous studies have shown that this pathway is active in malignant melanocytes. In addition, previous work has shown that multi-level targeting of this pathway might be more effective than targeting the pathway at a single level. In this review, we discuss targeting different members of this pathway, potential escape mechanisms, classes of specific molecular inhibitors, and development of NVP-BEZ235, a novel dual PI3k/mTOR inhibitor.

Keywords: Mammalian target of rapamycin, melanoma, phosphatidylinositol 3-kinase.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 13
ISSUE: 2
Year: 2013
Page: [165 - 174]
Pages: 10
DOI: 10.2174/1568009611313020006
Price: $58